# CD19-targeting 3rd Generation CAR T Cells for Refractory B Cell Malignancy - a Phase I/IIa Trial.

> **NCT02132624** · PHASE1,PHASE2 · COMPLETED · sponsor: **Uppsala University** · enrollment: 15 (actual)

## Conditions studied

- B Cell Lymphoma
- B Cell Leukemia

## Interventions

- **BIOLOGICAL:** Autologous 3rd generation CD19-targeting CAR T cells

## Key facts

- **NCT ID:** NCT02132624
- **Lead sponsor:** Uppsala University
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-04
- **Primary completion:** 2017-05-31
- **Final completion:** 2017-05-31
- **Target enrollment:** 15 (ACTUAL)
- **Last updated:** 2017-10-30

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02132624

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02132624, "CD19-targeting 3rd Generation CAR T Cells for Refractory B Cell Malignancy - a Phase I/IIa Trial.". Retrieved via AI Analytics 2026-07-05 from https://api.ai-analytics.org/clinical/NCT02132624. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*